The Toxicity Of Aromatase Inhibitors May Explain Lack Of Overall Survival Improvement
 

The toxicities associated with aromatase inhibitors (AIs) may explain the lack of overall survival improvement compared with tamoxifen, according to a study published August 22 in the Journal of The National Cancer Institute. AIs are a class of drugs used to treat breast cancer in postmenopausal women...

More...